Encouraging early data have been seen with the studied combination, as in a Phase Ib investigator sponsored trial from Japan called REGONIVO
News
Robots to help produce new class of antibiotics
The antibiotics, known as class II polyketides, are also naturally produced by soil bacteria and have antimicrobial properties.
Boehringer expands IPF pipeline with addition of BBT-877
Under the terms of the deal Bridge Biotherapeutics will receive upfront and near term payments of 45 million Euros and is eligible to receive up to more than 1.1 billion Euros in potential payments.
Mallinckrodt halts mid-stage Acthar trial citing pneumonia risk
ALS is a progressive neurodegenerative disease that affects motor neuron cells in the brain and the spinal cord.
Novartis’ sickle cell drug wins FDA priority review
The governing body accepted the company’s Biologics License Application for prevention of vaso-occlusive crises.
Gender imbalance expected in senior pharma roles until 2090
More than 85% of companies have no women executives on their main boards, only 9% of executive directors on main boards are women, and a mere 17% of FTSE350 executive committee members are women.
Boots UK to offer cystitis test
During the pilot over the last seven months over 1,000 customers accessed the service, with the majority of them completing the service in the same day.
‘World’s most accurate blood test’ for prostate cancer launched in UK
The Mitomic Prostate Test has a 92% sensitivity, which means that men with a positive result can be referred for immediate medical intervention.
PureTech acquires LYT-100 to treat lymphedema
The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies.
Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
Roche’s Genentech inks deal with Sosei Heptares
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments.
NICE U-turn for Kisqali in breast cancer
NICE has recommended Novartis’ Kisqali just three months after its initial rejection.
Pistoia Alliance launches FAIR implementation ‘toolkit’
The ‘toolkit’, will be available to help companies implement the FAIR guiding principles for data management and stewardship.
NHS rolls out staff retention scheme
A new ‘transfer window’ lets staff move within the NHS between areas while developing new skills.
Abcam acquires EdiGene’s cell lines and lysates portfolio
Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings in the current financial year.
